Lysine clonixinate versus aspirin in the treatment of gonarthrosis

Lysine clonixinate (2-[3-chloro-o-toluidine] piridin-3 lysine carboxylate) is a nonsteroidal anti-inflammator drug acting mainly at the peripheral level. Preclinical and clinical pharmacologic studies have established the efficacy and tolerability of lysine clonixinate—good efficacy with a very low incidence of side effects. The efficacy of lysine clonixinate was assessed in patients on days 0, 2, 7, and 15 by rating swelling, warmth, redness, and pain on active and passive movement and pressure. Tolerability was assessed by anamnesis at each control day and by fecal occult blood determination at baseline and at the end of the study. The anti-inflammatory and analgesic efficacy of lysine clonixinate was statistically higher than that of aspirin as assessed on almost all clinical parameters. The greater efficacy of lysine clonixinate was associated with excellent tolerability—none of the 53 lysine clonixinate-treated patients showed occult blood in the feces whereas 19 to the 55 aspirin-treated patients showed positive fecal occult blood at the end of the study.